Brookline Capital Markets analyst Leah Rush Cann initiates coverage on CTI BioPharma (NASDAQ: CTIC) with a Buy rating and a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE